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101,908 PLN and 99,710 PLN respectively in group I and
53,646 PLN and 65,466 PLN respectively in group II.
PegINF + R in comparison to INF + R was cost-effective
in group I, with ICER 2826 PLN/LYG and 4793
PLN/OALY gained, and dominant in group 2. Changing
in value of key drivers for sensitivity analysis did not have
any signiﬁcant effect on the ICER. CONCLUSION: In
HCV genotype1 infected patients PegINF + R appears to
be cost-effective when compared with INF + R and within
a Polish context offers substantial beneﬁt at reasonable
cost. In HCV genotype non1 infected patients PegINF +
R is more effective and less costly than INF + R.
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Voriconazole is a triazole antifungal recently approved
for the ﬁrst-line treatment of proven or probable invasive
aspergillosis, a nosocomial infection with a high mortal-
ity rate. Conventional amphotericin B (CAB) has long
been the standard therapy for this condition. In a large
randomized clinical trial of primary therapy for invasive
aspergillosis, voriconazole has been shown to be superior
to CAB in terms of global response and survival beneﬁt
as well as fewer adverse events. In this trial, initial ran-
domized therapy could be followed by other licensed anti-
fungal therapy (OLAT) for progression of disease or
intolerance. Voriconazole is also available both intra-
venously and orally. CAB is only available as an intra-
venous formulation. OBJECTIVES: The direct costs and
effectiveness (deﬁned as life year saved) of starting
therapy with voriconazole vs. CAB have been compared
from the Belgian public health care system’s perspective.
METHODS: A decision tree, spanning a 12-week time
horizon, was populated with efﬁcacy and resources use
data, prospectively collected from the large comparative
trial mentioned above as well as from international and
national expert panels. RESULTS: For patients >40kg
(mean = 65kg), the average treatment cost per patient was
€21,298 in the voriconazole arm and €19,492 in the CAB
arm. The incremental cost per life year saved of treating
with voriconazole was €6085. For patients <40kg (mean
= 35kg), the average treatment cost per patient was
€16,863 in the voriconazole arm and €17,111 in the CAB
arm. CONCLUSION: For patients >40kg, the incremen-
tal cost per life year saved of treating with voriconazole
appears to be reasonable compared to its beneﬁt. For
patients <40kg, voriconazole was a dominant therapeu-
tic alternative. An observational study will be initiated in
order to conﬁrm these results.
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OBJECTIVES: To assess the cost-effectiveness and cost-
utility of preventing post-exposure inﬂuenza infection
with the neuraminidase inhibitor oseltamivir from a
health care payer’s perspective in the UK. METHODS:
Based on clinical trial data and data from the literature a
simulation model was developed to predict morbidity and
mortality due to inﬂuenza and it’s speciﬁed complications,
comparing oseltamivir post-exposure prophylaxis for 10
days with no prophylaxis within families. The model was
run for three different attack rates (8%, 12%, 15%).
Robustness of the results was tested by uni- and multi-
variate as well as probabilistic sensitivity analyses.
RESULTS: Post-exposure prophylaxis with oseltamivir
results in reduced morbidity, i.e. less inﬂuenza cases and
hence less hospitalizations and mortality due to inﬂuenza.
However, comparing oseltamivir with no prophylaxis for
the attack rates of 8%, 12%, and 15% the mean costs
per QALY gained are £31,656, £19,264 and £14,241; the
mean costs per case avoided are £468, £291, and £221
respectively. CONCLUSIONS: Post-exposure prophy-
laxis is a valuable intervention particularly in seasons
with higher attack rates such as pandemic situations.
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OBJECTIVES: Invasive aspergillosis is a life-threatening
infection with a very high mortality. Voriconazole (VOR)
is a broad-spectrum triazole that is active against
Aspergillus species. Our objective is to carry out an eco-
nomic evaluation of VOR versus Amphotericin B (AMB)
for the treatment of invasive aspergillosis in Spain.
METHODS: A cost-effectiveness analysis was performed
through a decision analytical model. Effectiveness data
were obtained from a multicenter-randomized trial
showing that VOR was more effective than AMB in treat-
ing invasive aspergillosis in immunosupressed patients
(Herbrecht R, et al. N Engl J Med 2002;347:408–415).
Health care resource utilisation was taken from the afore-
mentioned clinical trial and a local expert panel. Only
direct medical costs were included in the model (drug
acquisition, length of stay, diagnostic procedures and
treatment of therapeutic failures). Drug acquisition costs
